ClinicalTrials.gg
Active, not recruitingNCT06212752Updated Aug 26, 2026Results posted

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

A Phase 3 interventional study of Pembrolizumab Formulated with Berahyaluronidase Alfa and Pemetrexed in Metastatic Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 18 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc — 14 open to participants now, 26 under way, 18 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck & Co., Inc.

Enrollment
73rd of 88
39 · median 149
Started
2023
with 7 others
Phase 3
38 of 91
9 open now
Primary completion
2024-11
later than 2 of 25 live
Registered
75th of 91
by date

Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 73rd largest by enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2023, is one of 38 in phase 3, reaches primary completion later than 2 of the 25 other live ones, and was the 75th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab (+) berahyaluronidase alfa vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult Japanese participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are pembrolizumab (+) berahyaluronidase alfa subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.

Read the detailed description

Japan extension study will require approximately six years which includes one additional year (beyond the global study's last participant last study related contact) from the time the first participant (or their legally acceptable representative) provides informed consent until the last participant's last study related contact to complete.

The Japan extension study will include participants previously enrolled in Japan in the global study for MK-3475A-D77 (NCT05722015) plus the study will continue to enroll participants in Japan until the sample size for participants in Japan reaches approximately 39.

As of Amendment 1 of the supplemental statistical analysis plan (effective date: 23 Aug 2024), patient reported outcomes will no longer be the secondary outcome measures of the study.

Effective as of Amendment 4, participants will no longer be able to start a second course of pembrolizumab. Participants already receiving second course treatment at the time of amendment 4 should continue to receive second course treatment.

03

Conditions studied

  • Metastatic Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Has or cytologically confirmed diagnosis of squamous or non-squamous Non-small Cell Lung Cancer (NSCLC)
  • Must provide sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated
  • Has a of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • Has received prior systemic anticancer therapy for NSCLC
  • Has received prior systemic anticancer therapy including agents within 4 weeks before randomization
  • Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicity requiring
  • Has received radiation therapy to the lung (>30 Gray) within 6 months of start of study intervention
  • Has received a live or within 30 days before the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
  • Has a known additional that is progressing or has required active treatment within the past 3 years
  • Has an active disease that has required systemic treatment in past 2 years
  • Has an active infection requiring systemic therapy
  • Has a history of (HIV) infection
  • Has a history of or C
  • Has not adequately recovered from major surgery or has ongoing surgical complications
  • Has a history of allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy

    Japanese participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated with Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for18 cycles (up to approximately108 weeks) in combination with platinum doublet chemotherapy.

    Biological: Pembrolizumab Formulated with Berahyaluronidase Alfa · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-paclitaxel · Drug: Filgrastim · Drug: Pegylated filgrastim

  • Active comparator
    Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy

    Japanese participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy.

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-paclitaxel · Biological: Pembrolizumab · Drug: Filgrastim · Drug: Pegylated filgrastim

Interventions

  • BiologicalPembrolizumab Formulated with Berahyaluronidase Alfa

    Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may have been eligible for second course if they met certain protocol-specified criteria prior to study amendment 4.

    Also known as: MK-3475A

  • Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.

    Also known as: Alimta

  • Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.

    Also known as: Platinol-AQ

  • Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.

  • Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.

    Also known as: Taxol

  • Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.

    Also known as: Albumin-bound paclitaxel

  • BiologicalPembrolizumab

    Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may have been eligible for second course if they met certain protocol-specified criteria prior to study amendment 4.

    Also known as: MK-3475, KEYTRUDA

  • Filgrastim will be administered as per the schedule specified for the arm.

  • Pegylated filgrastim will be administered as per the schedule specified for the arm.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). The percentage of participants with CR or PR were reported.

    Time frame: Up to ~ 16 months

Secondary outcomes

  1. Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose

    AUC0-6 weeks was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time from zero to 6 weeks. Blood samples were collected at pre-specified timepoints to determine AUC0-6 weeks. Per protocol, geometric mean AUC0-6 weeks value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.

    Time frame: Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days4, 15, 29, and 42 postdose (cycle length = 42 days)

  2. Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State

    Ctrough is defined as the trough concentration at steady-state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough.

    Time frame: Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)

  3. Cycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose

    Cmax was defined as the maximum serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, geometric mean Cmax value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.

    Time frame: Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)

  4. Cycle 1: Trough Serum Concentration (Ctrough) of Pembrolizumab After the First Dose

    Ctrough was defined as the lowest serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Ctrough. Per protocol, geometric mean Ctrough value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.

    Time frame: At designated time points (Up to ~28 months)

  5. Cycle 3: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab at Steady State

    AUC0-6 weeks was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time from zero to 6 weeks. Blood samples were collected at pre-specified timepoints to determine AUC0-6 weeks. Per protocol, geometric mean AUC0-6 weeks value of pembrolizumab at steady state of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and pembrolizumab in arm 2 was presented.

    Time frame: At designated time points (Up to ~28 months)

  6. Cycle 3: Maximum Serum Concentration (Cmax) of Pembrolizumab at Steady State

    Cmax was defined as the maximum serum concentration of pembrolizumab reached at steady state. Blood samples were collected at pre-specified timepoints to determine Cmax. Per protocol, geometric mean Cmax value of pembrolizumab at steady state of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and pembrolizumab in arm 2 was presented.

    Time frame: Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)

  7. Number of Participants Who Test Positive for Anti-Drug Antibodies (ADAs) for Pembrolizumab

    Blood samples are to be collected at designated time points for the determination of the presence or absence of anti-pembrolizumab antibodies. The percentage of participants who develop anti pembrolizumab antibodies will be reported.

    Time frame: At designated time points (Up to ~28 months)

  8. Progression-free Survival (PFS) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.

    Time frame: Up to ~59 months

  9. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to ~59 months

  10. Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)

    For participants who show confirmed CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to ~59 months

  11. Number of Participants Who Experienced at Least One Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an AE will be reported for Arms 1 and 2.

    Time frame: Up to~28 months

  12. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported for Arms 1 and 2.

    Time frame: Up to~25 months

07

Results

Posted Nov 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
Started2811
Completed00
Not completed2811
Withdrew: Death53
Withdrew: Participants ongoing238

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). The percentage of participants with CR or PR were reported.

Time frame:
Up to ~ 16 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
Objective Response Rate (ORR)64.3 (44.1 to 81.4)18.2 (2.3 to 51.8)
SecondaryCycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose

AUC0-6 weeks was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time from zero to 6 weeks. Blood samples were collected at pre-specified timepoints to determine AUC0-6 weeks. Per protocol, geometric mean AUC0-6 weeks value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.

Time frame:
Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days4, 15, 29, and 42 postdose (cycle length = 42 days)
Reported as:
Geometric mean · µg·day/mL
Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose
µg·day/mLArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose1864.76 ± 22.181697.98 ± 18.50
Statistical analysis
  • Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy vs Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy · Geometric mean ratio (gmr): 1.10 · 95% CI 0.95 to 1.27GMR and associated 96% confidence interval (Cl) were calculated using the Welch's t test. GMR was calculated as geometric mean (GM) of Pembrolizumab Formulated with Berahyaluronidase Alfa to GM of Pembrolizumab.
SecondaryCycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State

Ctrough is defined as the trough concentration at steady-state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough.

Time frame:
Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)
Reported as:
Geometric mean · µg/ml
Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State
µg/mlArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State45.11 ± 35.5830.86 ± 24.93
Statistical analysis
  • Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy vs Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy · Gmr: 1.46 · 95% CI 1.14 to 1.88GMR and associated 95% CI were calculated using the Welch's t test. GMR was calculated as geometric mean (GM) of Pembrolizumab Formulated with Berahyaluronidase Alfa to GM of Pembrolizumab.
SecondaryCycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose

Cmax was defined as the maximum serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, geometric mean Cmax value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.

Time frame:
Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)
Reported as:
Geometric mean · µg/ml
Cycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose
µg/mlArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
Cycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose71.54 ± 23.7141.9 ± 16.4
SecondaryCycle 1: Trough Serum Concentration (Ctrough) of Pembrolizumab After the First Dose

Ctrough was defined as the lowest serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Ctrough. Per protocol, geometric mean Ctrough value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.

Time frame:
At designated time points (Up to ~28 months)
Reported as:
Geometric mean · µg/ml
Cycle 1: Trough Serum Concentration (Ctrough) of Pembrolizumab After the First Dose
µg/mlArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
Cycle 1: Trough Serum Concentration (Ctrough) of Pembrolizumab After the First Dose23.62 ± 27.916.27 ± 29.7
SecondaryCycle 3: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab at Steady State

AUC0-6 weeks was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time from zero to 6 weeks. Blood samples were collected at pre-specified timepoints to determine AUC0-6 weeks. Per protocol, geometric mean AUC0-6 weeks value of pembrolizumab at steady state of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and pembrolizumab in arm 2 was presented.

Time frame:
At designated time points (Up to ~28 months)
Reported as:
Geometric mean · µg•day/ml
Cycle 3: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab at Steady State
µg•day/mlArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
Cycle 3: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab at Steady State3116 ± 27.32514 ± 17.3
SecondaryCycle 3: Maximum Serum Concentration (Cmax) of Pembrolizumab at Steady State

Cmax was defined as the maximum serum concentration of pembrolizumab reached at steady state. Blood samples were collected at pre-specified timepoints to determine Cmax. Per protocol, geometric mean Cmax value of pembrolizumab at steady state of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and pembrolizumab in arm 2 was presented.

Time frame:
Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)
Reported as:
Geometric mean · µg/mL
Cycle 3: Maximum Serum Concentration (Cmax) of Pembrolizumab at Steady State
µg/mLArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
Cycle 3: Maximum Serum Concentration (Cmax) of Pembrolizumab at Steady State108.1 ± 25.3159.8 ± 13.2
SecondaryNumber of Participants Who Test Positive for Anti-Drug Antibodies (ADAs) for Pembrolizumab

Blood samples are to be collected at designated time points for the determination of the presence or absence of anti-pembrolizumab antibodies. The percentage of participants who develop anti pembrolizumab antibodies will be reported.

Time frame:
At designated time points (Up to ~28 months)

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)

PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.

Time frame:
Up to ~59 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS is defined as the time from randomization to death due to any cause.

Time frame:
Up to ~59 months

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)

For participants who show confirmed CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

Time frame:
Up to ~59 months

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Experienced at Least One Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an AE will be reported for Arms 1 and 2.

Time frame:
Up to~28 months

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported for Arms 1 and 2.

Time frame:
Up to~25 months

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 16 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy5/28 (17.9%)12/28 (42.9%)28/28 (100%)
Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy3/11 (27.3%)3/11 (27.3%)11/11 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
CataractEye disorders0/281/11
ColitisGastrointestinal disorders0/281/11
PyrexiaGeneral disorders1/281/11
PneumoniaInfections and infestations2/281/11
Decreased appetiteMetabolism and nutrition disorders0/281/11
Febrile neutropeniaBlood and lymphatic system disorders2/280/11
PneumonitisRespiratory, thoracic and mediastinal disorders2/280/11
Cardiac failure congestiveCardiac disorders1/280/11
EnterocolitisGastrointestinal disorders1/280/11
EncephalitisInfections and infestations1/280/11
Most frequent other events
Showing 10 of 79
Most frequent other events
EventArm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet Chemotherapy
AnaemiaBlood and lymphatic system disorders12/289/11
NeutropeniaBlood and lymphatic system disorders13/284/11
ConstipationGastrointestinal disorders11/285/11
DiarrhoeaGastrointestinal disorders3/285/11
ThrombocytopeniaBlood and lymphatic system disorders9/284/11
Alanine aminotransferase increasedInvestigations5/284/11
Decreased appetiteMetabolism and nutrition disorders4/284/11
NauseaGastrointestinal disorders10/283/11
LeukopeniaBlood and lymphatic system disorders6/283/11
PyrexiaGeneral disorders6/283/11

Baseline characteristics

All Japanese participants who were randomized to the global study (NCT05722015) or to the extension portion.

Age, Continuous
Age, Continuous(Years)Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet ChemotherapyTotal
Mean68.3 ± 9.070.7 ± 8.269.0 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet ChemotherapyTotal
Female437
Male24832
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet ChemotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino281139
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet ChemotherapyTotal
American Indian or Alaska Native000
Asian281139
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet ChemotherapyTotal
ECOG = 018624
ECOG = 110515
Histology (squamous vs. nonsquamous)
Histology (squamous vs. nonsquamous)(Participants)Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet ChemotherapyTotal
Non-squamous14923
Squamous14216
Programmed Cell Death Ligand 1 (PD-L1) Status
Programmed Cell Death Ligand 1 (PD-L1) Status(Participants)Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet ChemotherapyArm 2: Pembrolizumab + Platinum Doublet ChemotherapyTotal
TPS <1%12618
TPS 1-49%11415
TPS ≥50%213
Unknown303
08

Study locations

18 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Nov 2024, 16 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 16 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 19, 2024
StartActual
Jun 13, 2023
Primary completionActual
Nov 6, 2024
CompletionEst.
May 22, 2028
Results first posted
Nov 12, 2025
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06212752
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Jun 13, 2023
Primary completion
Nov 6, 2024
Completion
May 22, 2028 (estimated)
Results posted
Nov 12, 2025
Last update
Aug 26, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion